Tiago R. Velho

Prof. Dr. Tiago R. Velho

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2016 in Biomaterials
Verified
Journal Article
Closed access
ARAkhilesh Rai
Akhilesh Rai
SPSandra Pinto
Sandra Pinto
TVTiago R. Velho
Tiago R. Velho
AFAndré F. Ferreira
André F. Ferreira
CMCatarina Ferreira Moita
Catarina Ferreira Moita
LFLino Ferreira
Lino Ferreira

1 January 2022 in Brazilian Journal of Cardiovascular Surgery
Verified
Journal Article
Open access
TVTiago R. Velho
Tiago R. Velho
RPRafael Maniés Pereira
Rafael Maniés Pereira
FFFrederico Fernandes
Frederico Fernandes
NGNuno Carvalho Guerra
Nuno Carvalho Guerra
RFRicardo Ferreira
Ricardo Ferreira
ÂNÂngelo Nobre
Ângelo Nobre
The increase in the prevalence of aortic stenosis due to an aging population has led to an increasing number of surgical aortic valve replacements. Over the past 20 years, there has been a major shift in preference from mechanical to bioprosthetic valves. However, despite efforts, there is still no "ideal" bioprosthesis. It is crucial to understand the structure, biology, and function of native heart valves to design more intelligent, strong, durable, and physiological heart valve tissues. A comprehensive review of the literature was performed to identify articles reporting the basic mechanisms of bioprosthetic valve dysfunction and the biology of native valve cells. Searches were run in PubMed, MEDLINE® (the Medical Literature Analysis and Retrieval System Online), and Google Scholar. Terms for subject heading and keywords search included “biological heart valve dysfunction”, “bioprosthesis dysfunction”, “bioprosthesis degeneration”, and “tissue heart valves”. All the relevant findings are summarized in the appropriate subsections. Structural dysfunction is a logical and expected consequence of the chemical, mechanical, and immunological processes that occur during fixation, manufacture, and implantation. Biological prosthesis valve dysfunction is a clinically significant process. It has become a major issue considering the growing rate of bioprosthesis implantation and improved long-term patient survival. Understanding bioprosthetic aortic valve degeneration from a basic science perspective is a key point to improve technologic advances and specifications that lead to a new generation of bioprostheses.

1 January 2012 in Drugs in Context
Verified
Journal Article
Open access
TVTiago R. Velho
Tiago R. Velho
Melanoma is one of the most aggressive cancers, and it is estimated that 76,250 men and women will be diagnosed with melanoma of the skin in the USA in 2012. Over the last few decades many drugs have been developed but only in 2011 have new drugs demonstrated an impact on survival in metastatic melanoma. A systematic search of literature was conducted, and studies providing data on the effectiveness of current and/or future drugs used in the treatment of metastatic melanoma were selected for review. This review discusses the advantages and limitations of these agents, evaluating past, current and future clinical trials designed to overcome such limitations. To date, there are four drugs approved by the Food and Drug Administration for melanoma (dacarbazine, interleukin-2, ipilimumab and vemurafenib). Despite efforts to develop new drugs, few of them have demonstrated any clinical benefits. Approved in 1975, dacarbazine remains the gold standard in chemotherapy, although ipilimumab and vemurafenib have raised many hopes in the last few years. Combining dacarbazine or other chemotherapy agents with new pharmacological agents may be a new way to achieve better clinical responses in patients with metastatic melanoma. Advances in the molecular knowledge of melanoma have led to major improvements in the treatment of patients with metastatic melanoma, providing new targets and insights. However, heterogeneity amongst study populations, different approaches to treatment and the different melanoma types and localisations included in the trials makes their comparison difficult. New studies focusing on drugs developed in recent decades are warranted.

7 December 2022 in eLife
Verified
Journal Article
Open access
ACAngelo Ferreira Chora
Angelo Ferreira Chora
DPDora Pedroso
Dora Pedroso
EKEleni Kyriakou
Eleni Kyriakou
NPNadja Pejanovic
Nadja Pejanovic
HCHenrique Colaço
Henrique Colaço
LMLuis Moita
Luis Moita
Anthracyclines are among the most used and effective anticancer drugs. Their activity has been attributed to DNA double-strand breaks resulting from topoisomerase II poisoning and to eviction of histones from select sites in the genome. Here, we show that the extensively used anthracyclines Doxorubicin, Daunorubicin, and Epirubicin decrease the transcription of nuclear factor kappa B (NF-κB)-dependent gene targets, but not interferon-responsive genes in primary mouse (Mus musculus) macrophages. Using an NMR-based structural approach, we demonstrate that anthracyclines disturb the complexes formed between the NF-κB subunit RelA and its DNA-binding sites. The anthracycline variants Aclarubicin, Doxorubicinone, and the newly developed Dimethyl-doxorubicin, which share anticancer properties with the other anthracyclines but do not induce DNA damage, also suppressed inflammation, thus uncoupling DNA damage from the effects on inflammation. These findings have implications for anticancer therapy and for the development of novel anti-inflammatory drugs with limited side effects for life-threatening conditions such as sepsis.

14 February 2016 in Swiss Medical Weekly
Verified
Journal Article
Open access
TVTiago R. Velho
Tiago R. Velho
ISIsa Santos
Isa Santos
PPPedro Póvoa
Pedro Póvoa
LMLuis Moita
Luis Moita
International peer-reviewed medical journal based on online-first publication

27 January 2025 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
TVTiago R. Velho
Tiago R. Velho
FPFrancisco Pinto
Francisco Pinto
RFRicardo Ferreira
Ricardo Ferreira
RPRafael Maniés Pereira
Rafael Maniés Pereira
ADAntónio Duarte
António Duarte
LMLuis Moita
Luis Moita